The mechanisms for activation of a vascular platelet component of hemostasis in the stroke recovery period and the ways of their correction

Objective: to assess changes in the vascular platelet component of hemostasis in patients in different recovery periods of ischemic stroke (IS).

Patients and methods. The investigation enrolled 73 patients with prior IS. According to the remoteness of stroke, the patients were divided into two groups: 1) 41 patients with a stroke remoteness of 1 to 6 months (an early recovery period); 2) 32 patients with that of 7 to 12 months (a late recovery period). In addition, a group of patients with recurrent stroke was identified to evaluate the efficiency of secondary prevention. A control group consisted of 30 healthy volunteers. All the patients took acetylsalicylic acid (ASA). Medical history data and laboratory and instrumental findings were analyzed. To assess the vascular platelet component of hemostasis, platelet aggregation with inductors was studied applying optical aggregometry; enzyme immunoassay was used to estimate the concentrations of the inflammatory marker myeloperoxidase and the endothelial dysfunction (ED) markers sICAM-1 and sE-selectin.

Results and discussion. The patients were found to have enhanced platelet aggregation with inductors; moreover, this was more pronounced in the patients with recurrent stroke than in those with new-onset IS. This suggests that the vascular platelet component of hemostasis contributes to the progression of the disease and its unfavorable course and necessitates the monitoring of these parameters to choose optimal secondary prevention methods, such as replacement of ASA with clopidogrel or use of its combination with dipyridamol. The activity of chronic immune inflammation processes and ED was ascertained to be enhanced, which can contribute to the aggravation of cerebrovascular insufficiency and to the development of acute cerebrovascular accident.

Conclusion. In the recovery period of stroke, the follow-up monitoring of hemostatic parameters and immune inflammatory and ED markers is of importance in evaluating the efficiency of secondary prevention. For the successful prevention of recurrent strokes, it is necessary to prescribe adequate antiplatelet therapy, as well as drugs that have anti-inflammatory properties, affect intercellular interaction processes (ASA, clopidogrel, and statins), and suppress oxidative stress associated with endothelial inflammation (alpha-lipoic acid and succinic acid preparations).

1. Suslina ZA, Tanashyan MM, Lagoda OV. Atherosclerosis and ischemic disorders of cerebral circulation. Aterotromboz. 2009; (2):60-7. (In Russ.).

2. European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack. Cerebrovasc Dis. 2008;25(5):457-507. doi: 10.1159/000131083. Epub 2008 May 6.

3. Suslina ZA, Tanashyan MM, Ionova VG. Ishemicheskii insul't: krov', sosudistaya stenka, antitromboticheskaya terapiya [Ischemic stroke: blood, vascular wall, antithrombotic therapy]. Moscow: Meditsinskaya kniga; 2005. 248 p.

4. Smertina EG, Prokopenko SV, Ionova VG, et al. The state of hemostatic system and endothelial function in different subtypes of ischemic stroke in acute and restorative periods. Byulleten' sibirskoi meditsiny. 2009;8(1-2):72-7. (In Russ.).

5. Alvarez-Perez FJ, Castelo-Branco M, Alvarez-Sabin J. Usefulness of measurement of fibrinogen, D-dimer, D-dimer/fibrinogen ratio, C reactive protein and erythrocyte sedimentation rate to assess the pathophysiology and mechanism of ischaemic stroke. J Neurol Neurosurg Psychiatry. 2011 Sep;82(9):986-92. doi: 10.1136/jnnp.2010.230870. Epub 2011 Feb 4.

6. Fateh-Moghadam S, Htun P, Tomandl B, et al. Hyperresponsiveness of platelets in ischemic stroke. Thromb Haemost. 2007 Jun; 97(6):974-8.

7. Wiseman S, Marlborough F, Doubal F, et al. Blood markers of coagulation, fybrinolisis, endothelial dysfunction and inflammation in lacunar stroke versus non-lacunar stroke and non-stroke: systematic review and meta-analysis. Cerebrovasc Dis. 2014;37(1):64-75. doi: 10.1159/000356789. Epub 2013 Dec 21.

8. Baranova OA, Chekanov AV, Karneev AN, et al. Search for new markers of oxidative stress in cerebral ischemia to optimize therapeutic approaches. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2011;(12):25-31. (In Russ.).

9. Maksimova MYu, Komel'kova LV, Okhtova FR. Factors of intercellular interaction in ischemic stroke. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2014;(2):15-20. (In Russ.).

10. Fathollahi A, Massoud A, Amirzargar AA, et al. sICAM-1, sVCAM-1 and sE-Selectin Levels in Type 1 Diabetes. Fetal Pediatr Pathol. 2018 Feb;37(1):69-73. doi: 10.1080/15513815.2017.1405467. Epub 2018 Jan 16.

11. Shchul'kin AV. Effect of Mexidol on the development of excitotoxicity of neurons in vitro. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2012;(2):35-9. (In Russ.).

12. Skvortsova VI, Stakhovskaya LV, Nartsissov YaR, et al. Randomized double-blind placebo-controlled study of the efficacy and safety of Mexidol in the treatment of acute ischemic stroke. Insul't. 2006;(18):47-54. (In Russ.).

13. Voronina TA. Pioneer of antioxidant neuroprotection. 20 years in clinical practice. Russkii meditsinskii zhurnal. 2016;(1):1-5. (In Russ.).

14. Shchepankevich LA, Nikolaev YuA, Dolgova NA. Optimization of lipid-containing therapy in patients with ischemic stroke and type 2 diabetes. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2016; (2):42-5. (In Russ.).